📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. (2022)

First Author: Quinn TM

Attributed to: MICA: A new paradigm for testing pathway tractability in lung disease funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ebiom.2022.103856

PubMed Identifier: 35152152

Publication URI: http://europepmc.org/abstract/MED/35152152

Type: Journal Article/Review

Volume: 76

Parent Publication: EBioMedicine

ISSN: 2352-3964